Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

European Journal of Neurology

Volumn 15, Issue 6, 2008, Pages 598-604

  Utsugisawa, K ^a   Nagane, Y ^a   Suzuki, S ^b   Suzuki, N ^b  

^a Hanamaki General Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C0; C2; Cyclosporine microemulsion pre concentrate; Myasthenia gravis; Open trial

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CREATININE; CYCLOSPORIN A; INTERLEUKIN 2; PREDNISOLONE; PYRIDOSTIGMINE; TACROLIMUS;

ADULT; ANTIBODY TITER; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPERTENSION; MALE; MICROEMULSION; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS;

BODY MASS INDEX; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS;

EID: 43549098291     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02130.x     Document Type: Article

References (25)

1. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973 180 : 871 872.
2. Fujii Y, Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. Journal of Immunology 1988 141 : 3361 3369.
3. Cohen-Kaminsky S, Gaud C, Morel E, Berrih-Aknin S. High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters. Journal of Autoimmunity 1989 2 : 241 258.
4. McIntosh KR, Linsley PS, Bacha PA, Drachman DB. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein. Journal of Neuroimmunology 1998 87 : 136 146.
5. Utsugisawa K, Nagane Y, Obara D, Kondoh R, Yonezawa H, Tohgi H. Interleukin-2 production by peripheral blood mononuclear cells from patients with myasthenia gravis. European Neurology 2003 49 : 160 163.
6. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin; An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drug 2001 61 : 1957 2016.
7. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992 13 : 136 142.
8. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro. The Journal of Antibiotics (Tokyo) 1987 40 : 1256 1265.
9. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. Journal of Neurology 1997 244 : 542 547.
10. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000 55 : 448 450.
11. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T. The Japanese FK506 MG study group. Clinical study of FK506 in patients with myasthenia gravis. Muscle and Nerve 2003 28 : 570 574.
12. Lavrnic D, Vujic A, Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurologica Scandinavica 2005 111 : 247 252.
13. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis - a randomized pilot study. European Neurology 2005 53 : 146 150.
14. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. New England Journal of Medicine 1987 316 : 719 724.
15. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Annals of the New York Academy of Sciences 1993 681 : 539 551.
16. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1997 344 : 423 428.
17. Choc MG. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune®. International Journal of Dermatology 1997 36 (Suppl. 1 1 6.
18. 2 monitoring: a European consensus. Transplant International 2005 18 : 768 778.
19. Jaretzki A, III., Barohn RJ, Ernstoff RM, et al. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendation for clinical research standards. Neurology 2000 55 : 16 23.
20. Kawaguchi N, Kuwabara S, Nemoto Y, et al. The Study Group for Myasthenia Gravis in Japan. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. Journal of the Neurological Sciences 2004 224 : 43 47.
21. Kissel JT, Franklin GM. The Quality Standards Subcommittee of the American Academy of Neurology. Treatment of myasthenia gravis - a call to arms. Neurology 2000 55 : 3 4.
22. Utsugisawa K, Nagane Y, Yonezawa H, Obara D, Kondoh R, Tohgi H. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle and Nerve 2003 27 : 245 248.
23. 2 monitoring in clinical practice. Transplantation 2002 73 (Suppl. S19 S22.
24. Shibata N, Hayakawa T, Hoshino N, et al. Effect of obesity on cyclosporine trough concentrations in psoriasis patients. American Journal of Health-System Pharmacy 1998 55 : 1598 1602.
25. Lindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993 55 : 985 993.